Pfizer announced that their vaccine is “96% effective.”
Pfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
They said a trial of 10,000 participants aged 16 or older showed 95.6% effectiveness against the diseases, during a period when the Delta strain was prevalent.
The study also found that the booster shot had a favorable safety profile.
Pfizer had claimed initially its first vaccine was 95% effective.
It continued to slip.
Pfizer/BioNTech Vaccine Efficacy Slips To 84%–Get Ready For The 3rd Dose Push
The Palmieri Report is a Pro-America News Outlet founded by Jacob Palmieri. The Palmieri Report is dedicated to giving people the truth so that they can form their own informed political opinions. You can help us beat Big Tech by following us on GETTR , Telegram, and Rumble.
